Trials / Active Not Recruiting
Active Not RecruitingNCT05823766
Transforming Research and Clinical Knowledge in Traumatic Brain Injury Epileptogenesis Project (TRACK-TBI EPI)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- University of Pennsylvania · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The overarching goal of this study is to improve understanding of the long-range natural history of TBI and post-traumatic epilepsy (PTE) by extending follow-up of a previously enrolled cohort (TRACK-TBI) beyond the first 12 months after injury.
Detailed description
This longitudinal observational study is part of the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) initiative, a multi-institutional project designed to characterize the acute and longer-term clinical, neuroimaging, and blood biomarker features of TBI. TRACK-TBI enrolled TBI patients at 18 Level 1 Trauma Centers in the US, across the age and injury spectrum. This study will extend the follow-up period for TRACK-TBI participants. The extensive clinical, imaging, and biomarker data that has already been collected in these TRACK-TBI participants, in combination with the extended longitudinal data, will allow for the identification of risk factors, co-morbidities, and prognostic biomarkers of TBI. Consequently, the extension of study follow-up will help to determine negative neurological and psychological outcomes of individuals who experienced a TBI compared to healthy and orthopedic controls. The TRACK-EPI project aims to address the gaps in the existing literature and in the TRACK project regarding PTE. Post-traumatic epilepsy (PTE) is a common complication of traumatic brain injury (TBI), occurring in up to 20% of civilian patients and as many as 50% of military service members who suffer severe brain trauma, and 3-5% of those who suffer moderate TBI. Epilepsy resulting from brain trauma is often difficult to control with medical therapy, and is the cause of epilepsy in approximately 5% of patients referred to specialized epilepsy centers. PTE can be the result of TBI of any severity, although the risk is higher from severe TBI. PTE can arise through a variety of mechanisms, which may co-exist within a single patient. Focal brain injury, which results from penetrating trauma or focal contusions can result in epileptogenesis. Closed head injury can also produce diffuse injury, with shearing of axons and blood vessels, diffuse edema and ischemia, and secondary cellular damage through the release of inflammatory mediators. The clinical features of epilepsy, such as the frequency and severity of seizures, prevalence of associated co-morbidities, and responsiveness to therapy, may differ among these diverse mechanisms. Additionally, the neurophysiologic and imaging features of epileptogenicity also likely differ. Given the frequency of PTE, a more complete understanding of PTE etiology and prognosis is vital. Furthermore, it is likely that a sophisticated understanding of the subtypes of epilepsy resulting from brain trauma will be required to successfully develop anti-epileptogenic therapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | In-Person Outcome Assessment | Assessments will be administered to evaluate participant outcome status |
| PROCEDURE | 3T Magnetic Resonance Imaging (MRI) | Participants will be asked to complete a 3T MRI |
| BEHAVIORAL | Clinical Visit | Patients who screen positive for PTE will have an in-depth clinical visit |
| PROCEDURE | Blood Draw | Blood Draw for Plasma, DNA, Serum, RNA |
| PROCEDURE | EEG | An EEG will be performed on patients who screen positive for PTE at the clinical visit |
| BEHAVIORAL | Telephone Outcome Assessment | Assessments will be administered over the telephone to evaluate participant outcome status and screen for PTE |
Timeline
- Start date
- 2022-03-01
- Primary completion
- 2026-04-01
- Completion
- 2027-02-01
- First posted
- 2023-04-21
- Last updated
- 2026-03-09
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05823766. Inclusion in this directory is not an endorsement.